'The pre-specified expansion cohort success criteria was achieved and the study will now continue onto the Phase 2 trial in locally advanced breast cancer.
In the Phase 1b Preliminary Efficacy Analysis of the expansion cohort, eight patients to date have been evaluated for clinical response. Of these eight patients, one had a complete response; four had partial responses; two exhibited stable disease; and one had progressive disease. '
Well done PTX
Phase 2 to commence based on solid phase 1 results
Results, although on a small population, examplify efficacy, hence bring on phase 2
Interesting to see, as become available, the data on the other 5 patients.
PTX Price at posting:
10.0¢ Sentiment: Hold Disclosure: Held
